Balancing risks and therapeutic benefits. About adjuvant tamoxifen treatment for breast cancer patients

被引:7
|
作者
Sarradon-Eck, Aline [1 ]
Pellegrini, Isabelle [2 ]
机构
[1] MMSH, Ctr Norbert Elias, Equipe GReCSS PAS Anthropol Sante, F-130949 Aix En Provence, France
[2] Inst Paoli Calmette, INSERM, UMR SE4S 912, F-13273 Marseille 09, France
来源
SCIENCES SOCIALES ET SANTE | 2012年 / 30卷 / 01期
关键词
TREATMENT DECISION-MAKING; MEDICAL UNCERTAINTY; WOMENS PERCEPTIONS; CHEMOTHERAPY; HEALTH; EXPERIENCE;
D O I
10.3917/sss.301.0047
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
One of the main tools available for making bio-medical decisions about the best treatment to prescribe is the risk-benefit ratio. This article takes a contextual approach to the decision-making processes involved in the prescription of adjuvant tamoxifen as a mean of reducing the risk of relapse of breast cancer. Using anthropological descriptive methods, it examines the discrepancy between patients' and doctors' perceptions of the risks and benefits of the treatment and analyses their underlying logics. Representations of women are related to cancer (fear of the disease), its treatment (efficacy) and tamoxifen (fear of hormones and aging), and can lead to a symbolic hierarchy of treatments, whereas doctors' professional practices focus mainly on the prevention of the recurrence of cancers.
引用
下载
收藏
页码:47 / 71
页数:25
相关论文
共 50 条
  • [1] Tamoxifen, balancing risks and benefits
    Bergman, L
    Benraadt, J
    vanLeeuwen, FE
    NETHERLANDS JOURNAL OF MEDICINE, 1996, 49 (06): : 228 - 234
  • [2] Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
    Gail, MH
    Costantino, JP
    Bryant, J
    Croyle, R
    Freedman, L
    Helzlsouer, K
    Vogel, V
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) : 1829 - 1846
  • [3] Re: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
    Norsigian, J
    Napoli, M
    Brenner, BA
    Cody, N
    Batt, S
    Pearson, CA
    Potovsky-Beachell, L
    Cohen, VS
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (09) : 757 - 758
  • [4] Re: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer - Response
    Gail, MH
    Costantino, JP
    Bryant, J
    Croyle, R
    Freedman, L
    Helzlsouer, K
    Vogel, V
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (09) : 758 - 758
  • [5] Quality of life and adjuvant tamoxifen treatment in breast cancer patients
    Boehm, D. U.
    Lebrecht, A.
    Eckhardt, T.
    Albrich, S.
    Schmidt, M.
    Siggelkow, W.
    Kandelhardt, E.
    Koelbl, H.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (05) : 500 - 506
  • [6] Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer
    Davies, C
    Arriagada, R
    Ziegler, A
    Peralta, O
    REVISTA MEDICA DE CHILE, 1998, 126 (02) : 210 - 217
  • [7] Quality of life and adjuvant tamoxifen treatment in breast cancer patients
    Boehm, D.
    Lebrecht, A.
    Kantelhardt, E. J.
    Schmidt, M.
    Siggelkow, W.
    Koelbl, H.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S57 - S57
  • [8] The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer
    Malek, K
    Fink, AK
    Thwin, SS
    Gurwitz, J
    Ganz, PA
    Silliman, RA
    MEDICAL CARE, 2004, 42 (07) : 700 - 706
  • [9] Estimating the risks and benefits of tamoxifen for breast cancer chemoprevention in Korea
    Chang, M.
    EJC SUPPLEMENTS, 2008, 6 (07): : 75 - 75
  • [10] USEFULNESS OF HYSTEROSCOPY IN THE MANAGEMENT OF BREAST CANCER PATIENTS WITH TAMOXIFEN AS AN ADJUVANT TREATMENT
    Barreiro Garcia, J. M.
    Marti Sopena, M.
    Alvarez Sanchez, S.
    Delgado Espeja, J. J.
    Solano Calvo, J. A.
    Zapico Goni, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A152 - A153